- Organon Announces HADLIMA™ (adalimumab-bwwd) Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary
- Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2023
- Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 15, 2024
- Organon’s XACIATO™ (clindamycin phosphate) Vaginal Gel 2% Available Nationwide to Treat Bacterial Vaginosis (BV) in Females Aged 12 and Older
- Organon affirms 2023 revenue and Adjusted EBITDA guidance and provides 2024 outlook
More ▼
Key statistics
As of last trade Organon & Co (OGN:NYQ) traded at 18.62, -24.89% below its 52-week high of 24.79, set on May 01, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 18.50 |
---|---|
High | 18.68 |
Low | 18.43 |
Bid | 18.61 |
Offer | 18.62 |
Previous close | 18.45 |
Average volume | 2.23m |
---|---|
Shares outstanding | 255.64m |
Free float | 255.34m |
P/E (TTM) | 4.62 |
Market cap | 4.72bn USD |
EPS (TTM) | 3.99 USD |
Annual div (ADY) | 1.12 USD |
---|---|
Annual div yield (ADY) | 6.07% |
Div ex-date | Feb 23 2024 |
Div pay-date | Mar 14 2024 |
Data delayed at least 15 minutes, as of Mar 28 2024 14:29 BST.
More ▼